These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 2224862)

  • 1. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
    Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
    Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
    Berdeja JG; Hess A; Lucas DM; O'Donnell P; Ambinder RF; Diehl LF; Carter-Brookins D; Newton S; Flinn IW
    Clin Cancer Res; 2007 Apr; 13(8):2392-9. PubMed ID: 17438098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
    Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
    Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.